脾窦岸细胞血管瘤的CT和MRI表现  

CT and MRI findings of littoral cell angioma of spleen

作　　者：毛怡[1] 李学明[1] 郭应坤[1] 余建群[1] 宋彬[1] 郜发宝[1] 

机构地区：[1]四川大学华西医院放射科,成都610041

出　　处：《中华放射学杂志》2013年第1期60-63,共4页Chinese Journal of Radiology

基　　金：国家自然科学基金资助项目（81130027,81071204）;国家“973”基础研究资助项目（2011CB935800）

摘　　要：目的探讨脾窦岸细胞血管瘤（LCA）的临床及影像特点。方法回顾性分析经手术病理证实的12例LCA患者资料，其中9例行腹部CT平扫及增强扫描，2例行腹部MR平扫及增强扫描，1例同时行CT和MR检查。观察临床特征、CT以及MRI表现，并总结其影像特点。结果8例患者表现为脾大，无明显脾功能亢进症状；10例表现为多发的类圆形低密度病变，2例为单发病灶；12例均未见钙化以及包膜。CT扫描7例病灶边界清楚，3例边界欠清，平扫病灶多表现为稍低密度结节或脾脏密度不均匀；增强扫描为低密度结节，呈逐渐缓慢强化。在MRI上所有病灶边界清楚，呈长T1以及混杂长T2信号，其内可见点状低T2信号影，钆增强扫描呈高信号，并逐渐强化；在DWI、ADC图上病灶相对于正常的脾组织扩散增加。结论LCA在CT和MR图像上有一定的特异性，有助于临床诊断。Objective To determine the value of CT and MRI in the evaluation of littoral cell angioma（LCA） of spleen. Methods Two experienced radiologists retrospectively analyzed the clinical data, CT and MRI findings of 12 patients with pathology proven LCA of spleen. The patients underwent non- contrast enhanced CT scan, then enhanced CT （n = 10） and MRI （tt = 3 ） were performed. Results The majority of patients （8/12） showed splenomegaly, with no obvious signs and symptoms of hypersplenism. The majority of patients （10/12） had the uncountable hypodense lesions, a few （2/12） had only a single lesion. None of the lesions contained any calcification or envelopement. On CT, the majority （7/10） of the lesions demonstrated well circumscribed border, with some lesions （3/10） demonstrating a less distinct border. The enhanced scan for low-density nodules demonstrated slow progressive enhancement. On MRI, all the LAC had well circumscribed borders, and demonstrated T1 -hypointense and T2-hyperintense signalswith punctual hypointense in the T2WI, and progressive enhancement on the post contrast images. DWI showed an increased diffusion of the lesions compared to the normal appearing splenic tissue. Conclusion CT and MR imaging of littoral cell angioma of spleen has certain imaging characteristics, those particular findings may potentially aid in the diagnosis.

关 键 词：脾肿瘤 体层摄影术 X线计算机 磁共振成像 

分 类 号：R733.2[医药卫生—肿瘤]